Year
2023
-
Xtandi Shows Promise in Prostate Cancer Trial
-
J&J Settles Remicade Antitrust Suit
-
Six-month Ozempic shortage mostly over after weight-loss craze drained supply
-
FDA Green Lights Clinical Trial of Low-Dose Psilocybin
-
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
-
US FDA declines to approve AbbVie’s Parkinson’s disease therapy
-
FDA Approves Evkeeza for Kids With Ultra-Rare Cholesterol Disorder
-
EU Authorizes Dupixent for Young Kids With Severe Atopic Dermatitis
-
FDA Issues Warning Letter on Nyquil
-
FDA Approves Rezzayo, a Novel Echinocandin